ConductScience.org, home

Paper4479366

The biotransformation of cyclophosphamide in man: analysis of the variation in normal subjects.

Mouridsen HT and 2 others. Acta Pharmacol Toxicol (Copenh), 1974. Cited by 47 papers, by iCite.

Cite this record

ConductScience Library. The biotransformation of cyclophosphamide in man: analysis of the variation in normal subjects. Papers, record 4479366. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/4479366

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
The biotransformation of cyclophosphamide in man: analysis of the variation in normal subjects.
PubMed
Journal
Acta Pharmacol Toxicol (Copenh)
PubMed
Year
1974
PubMed
Publication types
Journal Article
PubMed
Citations, by iCite
47
iCite
Relative citation ratio, by iCite
2.55
iCite
Revised in PubMed
2019-08-29
PubMed

Authors3

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Mouridsen HTH T
2Faber OO
3Skovsted LL

Source PubMed

Download CSV of authors

Topics18

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
CyclophosphamideMajor topic
Adult
Age Factors
Aged
Analysis of Variance
Biotransformation
Body Weight
Carbon Radioisotopes
Chromatography, Thin Layer
Female
Half-Life
Humans
Injections, Intravenous
Male
Methods
Middle Aged
Sex Factors
Time Factors

Source PubMed

Download CSV of topics

Cited by18

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 47 citations.

PMIDTitleJournalYearIn PapersSource
16231966Clinical pharmacokinetics of cyclophosphamide.Clin Pharmacokinet2005https://conductscience.org/library/papers/16231966PubMed
9924440Proposal for the assessment of quantitative dermal exposure limits in occupational environments: Part 1. Development of a concept to derive a quantitative dermal occupational exposure limit.Occup Environ Med1998https://conductscience.org/library/papers/9924440PubMed
7358774[Blood level and urinary excretion of activated cyclophosphamide and its deactivation products in man (author's transl)].J Cancer Res Clin Oncol1980https://conductscience.org/library/papers/7358774PubMed
7307230Cyclophosphamide and dimethylsulfoxide in the treatment of squamous carcinoma of the lung. Therapeutic efficacy, toxicity, and pharmacokinetics.Cancer Chemother Pharmacol1981https://conductscience.org/library/papers/7307230PubMed
7127662Metabolism of high doses of cyclophosphamide.Cancer Chemother Pharmacol1982https://conductscience.org/library/papers/7127662PubMed
6882623Pharmacokinetics of cyclophosphamide in Kenyan Africans.Br J Clin Pharmacol1983https://conductscience.org/library/papers/6882623PubMed
6640827Pharmacokinetics of high-dose cyclophosphamide in patients with metastatic bronchogenic carcinoma.Cancer Chemother Pharmacol1983https://conductscience.org/library/papers/6640827PubMed
6469516Comparative effects of ASTA Z 7557 (INN mafosfamide) and cyclophosphamide on hematopoiesis in mice.Invest New Drugs1984https://conductscience.org/library/papers/6469516PubMed
6189661Clinical pharmacokinetics of commonly used anticancer drugs.Clin Pharmacokinet1983https://conductscience.org/library/papers/6189661PubMed
3757157Phase I clinical and pharmacokinetic study of cyclophosphamide administered by five-day continuous intravenous infusion.Cancer Chemother Pharmacol1986https://conductscience.org/library/papers/3757157PubMed
2661198Problems in the use of anticancer drugs in the elderly.Drugs1989https://conductscience.org/library/papers/2661198PubMed
1553250Detection of contamination with antineoplastic agents in a hospital pharmacy department.Pharm Weekbl Sci1992https://conductscience.org/library/papers/1553250PubMed
791322The effect of chloramphenicol and sulphaphenazole on the biotransformation of cyclophosphamide in man.Br J Clin Pharmacol1975https://conductscience.org/library/papers/791322PubMed
638469Haemodialysis during cyclophosphamide treatment.Br Med J1978https://conductscience.org/library/papers/638469PubMed
535136The disposition of cyclophosphamide in a group of myeloma patients.Cancer Chemother Pharmacol1979https://conductscience.org/library/papers/535136PubMed
497087Pharmacokinetics of cyclophosphamide and alkylating activity in man after intravenous and oral administration.Br J Clin Pharmacol1979https://conductscience.org/library/papers/497087PubMed
389529Clinical pharmacokinetics of cyclophosphamide.Clin Pharmacokinet1979https://conductscience.org/library/papers/389529PubMed
114397Pharmacokinetics of cyclophosphamide after prolonged low dose treatment in ovarian cancer patients.Eur J Drug Metab Pharmacokinet1979https://conductscience.org/library/papers/114397PubMed

Download CSV of cited by

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • References
  • Genes
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/4479366

GET https://conductscience.org/api/papers/v1/4479366/authors